Markets News
Market news and reports from Forbes.com
Updated: 1 hour 36 min ago
Retailers' Rude Awakening
The back-to-school shopping season is not yielding the kind of revenue they expected.
Categories: Forbes
Rough Road Ahead For Byetta
Amylin and Eli Lilly will have to calm investors' fears over its risky diabetes drug.
Categories: Forbes
Ricoh's On The Right Track
The copier and printer maker will acquire Ikon Office Solutions for $1.6 billion.
Categories: Forbes
Management Shake-Up At Fannie
The mortgage lender replaces three top executives but holds onto its CEO.
Categories: Forbes
Cell Genesys' Saving Grace
The biopharma's shares tanked on bad news from its prostate cancer drug, but earlier data could turn that around.
Categories: Forbes
Lehman Down But Not Out
The investment bank explores options as steep losses and write-downs hang overhead.
Categories: Forbes
Baosteel Slices Its Prices
China's largest steelmaker will slash its costs amid slowed economic growth and weakened demand.
Categories: Forbes
Durables Rule The Day
The Street came out swinging Wednesday, thanks in large part to strength in durables.
Categories: Forbes
Lehman Digs For Solutions
As subprime woes soldier on, the investment bank looks to sell its asset management unit.
Categories: Forbes
FDIC Under Pressure
The number of troubled U.S. banks rose to 117 in the second quarter, and there's no quick fix in sight.
Categories: Forbes
Shopping Season Slowdown
Consumer spending continues its downward spiral at a time when retailers yearn for an upswing.
Categories: Forbes
Cancer Plagues Cell Genesys
The company halted the study of its prostate cancer drug after it caused a high number of deaths.
Categories: Forbes
Baneful Byetta
Four new deaths stemmed from Amylin and Eli Lilly's diabetes drug, which sent investors running.
Categories: Forbes
Cuomo Investigates Goldman's Auction Rate Securities
The New York attorney general is investigating whether Goldman and Fidelity had a quid-pro-quo deal.
Categories: Forbes
High Oil Prices Prove Mixed Bag In China
Soaring crude costs benefit the country's oil producers but hurt the refiners.
Categories: Forbes
Back-To-School Blues
Retailers were a mixed bag on Wednesday as consumers continue to tighten their spending.
Categories: Forbes
Grim Reaper Hurts Cell Genesys
The biopharma company drops on halted study news, due to 100 deaths related to its prostate cancer drug.
Categories: Forbes
FDIC Feels The Banking Heat
The number of troubled U.S. banks rose to 117 in the second quarter, and there's no quick fix in sight.
Categories: Forbes
Bad News Byetta
Amylin Pharmaceuticals and Eli Lilly announce four new deaths among patients taking the diabetes drug.
Categories: Forbes
Outsourcing Pullback
As the IT sector suffers from U.S. economy pain, BT reportedly mulls a sale of its stake in Tech Mahindra.
Categories: Forbes
Bookmark this site
Bookmark this page
Make Us your homepage
